Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Injection devices, diagnostic platforms, and interventional tools place Becton, Dickinson and Company (BD) at the heart of patient care—but they also generate sprawling disclosures that can exceed 300 pages. Finding where BD details FDA observations, segment margins, or litigation reserves is a challenge for busy professionals.
Stock Titan solves that problem. Our AI reads every line the moment it hits EDGAR, giving you Becton Dickinson SEC filings explained simply. Curious about a BD quarterly earnings report 10-Q filing? Get an instant summary of Life Sciences revenue shifts. Need Becton Dickinson insider trading Form 4 transactions? Real-time alerts flag each executive move. For deeper dives, open any document and let the platform highlight:
- Becton Dickinson annual report 10-K simplified—R&D spending, product safety notes, global supply-chain risks.
- Becton Dickinson 8-K material events explained—device recalls, acquisitions, leadership changes.
- Becton Dickinson proxy statement executive compensation—how incentives align with BD Medical, Life Sciences, and Interventional performance.
Whether you’re benchmarking margins with our BD earnings report filing analysis or monitoring Becton Dickinson executive stock transactions Form 4, the platform keeps you ahead. Spend less time decoding footnotes and more time acting on insights—understanding Becton Dickinson SEC documents with AI means clarity on every risk factor, growth driver, and insider trade in one place.
Becton, Dickinson and Company and its finance subsidiary have filed a post-effective amendment to a Form S-3 shelf registration that covers the potential offering and sale of up to $10,000,000,000 of securities. The base prospectus allows BD to issue common stock, preferred stock, depositary shares, debt securities, warrants, purchase contracts and units, and permits Becton Dickinson Euro Finance S.à r.l. to issue debt securities fully and unconditionally guaranteed by BD, in one or more offerings over time.
BD explains that it expects to no longer qualify as a “well-known seasoned issuer” when it files its Form 10-K for the fiscal year ended September 30, 2025, so this amendment adds the disclosures required for a non-WKSI while keeping the shelf in place under Rule 415(a)(5). BD’s common stock trades on the NYSE under the symbol BDX, with a last reported sale price of $190.96 on November 24, 2025. BD had 285,418,551 shares of common stock outstanding as of October 31, 2025.
Becton, Dickinson and Company (BDX) reported that Robert L. Huffines and Jacqueline Wright were elected to its Board of Directors, effective December 1, 2025. At that time, the board will expand from twelve to fourteen members, adding two independent directors under New York Stock Exchange rules and the company’s governance principles.
Ms. Wright will join both the Audit Committee and the Compensation and Human Capital Committee, while Mr. Huffines will join the Audit Committee and the Corporate Governance and Nominating Committee. Each will receive a prorated grant of restricted stock units covering service from their election date through BD’s 2026 Annual Meeting of Shareholders, with specific grant details to be provided in a later amendment.
Becton, Dickinson and Company (BDX) reported an insider transaction on Form 4. Director Bertram L. Scott sold 217 shares of common stock at $176.58 on 11/07/2025. Following the sale, he beneficially owns 35,816 shares held directly. The filing was submitted by one reporting person.
BDX filed a Form 144 notice for a proposed sale of 217 shares of common stock. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as broker, with an aggregate market value $38,317.88, and an approximate sale date of 11/07/2025 on the NYSE.
The shares were acquired on 01/23/2025 via restricted stock vesting under a registered plan, recorded as Services Rendered. The filing also notes 286,627,469 shares outstanding.
Becton, Dickinson and Company (BDX) furnished a press release announcing financial results for its fourth fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to the report under Item 2.02.
The company notes that the release includes certain non-GAAP financial measures, with reconciliations and details presented in schedules accompanying Exhibit 99.1.
Becton, Dickinson and Company (BDX) director Carrie L. Byington reported an acquisition of derivative securities. On 11/04/2025, she acquired 34 rights to common stock under the BD Deferred Compensation Plan at a price of $178.71 per derivative security.
Following the transaction, she beneficially owns 1,675 derivative securities, held directly. Each right converts into one share of common stock. According to the plan terms, the securities are distributed after the director’s service ends or on dates the director specifies.
Becton, Dickinson and Company (BDX) reported a Form 4 for director Christopher Jones. On 11/04/2025, he acquired 168 derivative securities described as rights to common stock under the BD Deferred Compensation Plan, coded “A.” The filing lists a price of $178.71 for the derivative security.
Following this transaction, Jones beneficially owns 11,316 derivative securities on a direct basis. The securities convert to common stock on a one-for-one basis and are distributed following the end of his service as a director or on the date(s) he specifies. The filing notes that totals include rights acquired through dividend investment since the last report.
Becton Dickinson (BDX) reported an insider transaction by its EVP & President, Life Sciences. On 10/27/2025, the officer sold 57 shares of common stock at $186.01 per share. Following the sale, the officer beneficially owns 8,245 shares, held directly.
The filing notes the trade was made pursuant to a Rule 10b5-1 plan adopted on February 7, 2025, indicating a pre-set trading arrangement.
Becton, Dickinson and Company (BDX) filed a Form 144 for a proposed sale of 57 shares of common stock with an aggregate market value of $10,592.31. The planned sale is listed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of October 27, 2025.
The shares to be sold were acquired as Restricted Stock Units on August 20, 2025. Recent activity reported under a Rule 10b5-1 plan for Michael Feld includes 58 shares sold on September 26, 2025 for $10,499.74 and 57 shares sold on August 22, 2025 for $11,285.43.
Becton, Dickinson and Company (BDX) announced two updates. The company furnished a press release with preliminary unaudited revenue for its fourth quarter and full fiscal year ended September 30, 2025, provided as Exhibit 99.1.
BDX also disclosed a leadership transition. Executive Vice President and Chief Financial Officer Christopher J. DelOrefice informed the company on October 9, 2025, of his intention to resign effective December 5, 2025, to pursue a new professional opportunity. The company stated his departure is not due to any disagreement regarding financial statements, internal control, operations, policies or practices.
Upon his departure, Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, Vitor Roque, will serve as interim Chief Financial Officer and principal financial officer while a search for a permanent CFO is underway.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
